Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 3 Data Evaluating CVT-301 in Off Episodes of Parkinson's Disease

Source Link:: http://ir.acorda.com/investors/investor-news/investor-news-details/2016/Acorda-Announces-2015-AMPYRA-Sales-2016-Financial-Guidance-and-20162017-Clinical-Milestones-at-JP-Morgan-Healthcare-Conference/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ACOR

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Upcoming Clinical Trial Data on Dalfampridine in Post-Stroke Walking Difficulties (2H 2016) and CVT-301 for OFF Periods in Parkinson’s Disease (1Q 2017).

http://ir.acorda.com...

Additional Relevant Details “We are aiming to complete pivotal trials for CVT-301 in Parkinson’s disease and PLUMIAZ in seizure clusters this year; if successful, we plan to file New Drug Applications for both in 2017. We project that these two therapies could generate combined peak sales of over $700 million. We also expect to perform an interim analysis in our Phase 3 trial of dalfampridine for post-stroke walking deficits. This analysis, combined with results from our development efforts on a once-daily formulation of dalfampridine, will establish the next steps for the program.”

http://ir.acorda.com...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Feb 09, 2017

Occurred Source:

http://www.businesswire.com/news/home/20170209005506/en/

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Cvt-301, Off Episodes Of Parkinson's Disease